

AMENDMENTS TO THE SPECIFICATION

1-48. (canceled)

49. (previously presented): An isolated or recombinant polypeptide having SEQ ID NO: 3, 5, or 7.

50-53. (canceled)

54. (currently amended): A ~~fragment of a polypeptide of claim 49~~ consisting of nine, ten, or fifteen contiguous amino acids of SEQ ID NO: 3, 5, or 7, wherein the ~~fragment peptide~~ induces a specific antibody response against a polypeptide having the amino acid sequence of SEQ ID NO: 3, 5, or 7.

55. (canceled)

56. (previously presented): The fragment of claim 54 consisting of the polypeptide of any of Tables VIII to XLIX.

57. (previously presented): A composition which comprises the polypeptide of claim 49 and a pharmaceutically acceptable carrier.

58. (previously presented): A method of generating an immune response in a mammalian subject comprising exposing cells of the mammal's immune system to a polypeptide having SEQ ID NO: 3, 5, or 7, whereby an immune response to the polypeptide is generated.

59-62. (cancelled)

63. (previously presented): A polynucleotide that encodes the polypeptide of claim 49 or is fully complementary to the polynucleotide wherein T can also be U.

64-65. (canceled)

66. (previously presented): The polynucleotide of claim 63 having SEQ ID NO: 2, 4, or 6.

67-71. (canceled)

72. (previously presented): An isolated host cell modified to contain an expression vector for expressing the polynucleotide of claim 63.

73-74. (canceled)

75. (previously presented): A method for detecting the presence of cancer expressing a 254P1D6B protein in an individual comprising:

determining the level of expression of a polypeptide having SEQ ID NO: 3, 5, or 7 in a test tissue sample from an individual; and

comparing the level so determined to the level of expression that is evidenced in a normal tissue sample,

wherein the elevated expression of said polypeptide in the test sample versus the normal sample is an indication of the presence of cancer in the test tissue sample.

76. (canceled)

77. (currently amended): The method of claim 75 wherein the ~~cancer~~ tissue sample is selected from the group of ~~cancers~~ consisting of lung, ovary, breast pancreas, and prostate.

78. (canceled)

79. (currently amended): The ~~method of claim 58~~ polynucleotide of claim 63, wherein the polypeptide is encoded as a portion of ~~expressed in~~ a viral vector.

80. (currently amended): The ~~method~~ polynucleotide of claim 79 wherein the viral vector is selected from the group consisting of vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and Sindbis virus.